By contrast, in pancreatic cancer, increased H3K9me3 levels within the BCL2 antagonist/killer 1 (BAK1), BCL2 associated X (BAX), and BLC2-like 11 (BCL2L11) gene promoters were shown to inhibit the expression of these apoptotic effectors [59]. The gene discussed is BAK1; the disease is pancreatic neoplasm.